Registration for a live webinar on 'Phasing Out Animal Testing: A New Era for Pharmaceutical Innovation' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Anticancer target: definition
- Hsp90 - an ideal anti-cancer target?
- Geldanamycin - discovery in phenotypic screen
- Tumoricidal activity of ansamycins
- Inhibition of Hsp90-pp60 complex formation
- Hsp90-geldanamycin complex crystal structure
- Geldanamycin blocks Hsp90 biological function
- Mutant p53 requires functional Hsp90
- Transformation-specific effects of Hsp90
- Broad-spectrum effects of Hsp90
- Hsp90 inhibition may affect many cancers
- Hsp90 acts as a "buffer" of transformation
- Are Hsp90 inhibitors a solution to cancer?
- Tumor selectivity on Hsp90 inhibitors
- Validation of Hsp90 as a target
- Ansamycins
- Improved formulations of 17-AAG (1)
- Improved formulations of 17-AAG (2)
- Pharmacodynamic markers
- Radicicols
- ADP inside Hsp90/kinase pocket
- Purine-scaffold Hsp90 inhibitors (1)
- PU3 mimics the biological effects of GM
- Purine-scaffold Hsp90 inhibitors (2)
- Pyrazole derivatives
- Other Hsp90 inhibitors
- Conclusions from small Hsp90 inhibitors use
- Classical pharmacokinetic analysis relevance
- Inhibition of Hsp90 - cytostatic or cytotoxic?
- Limiting factors of anti-cancer potential (1)
- Limiting factors of anti-cancer potential (2)
- Limiting factors of anti-cancer potential (3)
- Hsp90 inhibitors translation to other diseases
- Concluding remarks
Topics Covered
- Heat shock protein 90 (Hsp90), a target in cancer
- Discovery of the first known Hsp90 inhibitor, geldanamycin
- Use of geldanamycin to understand the role of Hsp90 in malignant transformation
- Discovery of novel Hsp90 inhibitors
- Development and applications of Hsp90 inhibitors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Chiosis, G. (2007, October 1). Targeting cancer: designing drugs against Hsp90 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 20, 2025, from https://doi.org/10.69645/TELG8372.Export Citation (RIS)
Publication History
- Published on October 1, 2007
Financial Disclosures
- Dr. Gabriela Chiosis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.